Evidence map›Paper›PMID 32258424›Full record

ArticleJournal of psychiatry and brain science2020

Neuroprogression across the Early Course of Psychosis.

Kathryn E Lewandowski, Sylvain Bouix, Dost Ongur, Martha E Shenton

Abstract read
In one paragraph

Article in Journal of psychiatry and brain science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Connectome-based predictive modeling of early and chronic psychosis symptoms.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Normative modeling of thalamic nuclear volumes.medRxiv : the preprint server for health sciences · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kathryn E LewandowskiSchizophrenia and Bipolar Disorder Program, McLean Hospital, Belmont, MA 02478, USA.
Sylvain BouixDepartment of Psychiatry, Harvard Medical School, Boston, MA 02215, USA.
Dost OngurSchizophrenia and Bipolar Disorder Program, McLean Hospital, Belmont, MA 02478, USA.
Martha E ShentonDepartment of Psychiatry, Harvard Medical School, Boston, MA 02215, USA.

Funding

Human Connectome Project for Early PsychosisU01MH109977 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI BREIER, ALAN, SHENTON, MARTHA E. · 2016 to 2020
$5.5M
Neuroprogression across the Psychosis Spectrum in the Early Course of IllnessR01MH117012 · NIMH · MCLEAN HOSPITAL · PI LEWANDOWSKI, KATHRYN EVE · 2019 to 2023
$2.4M
NIMH NIH HHS R01 MH117012NIMH NIH HHS U01 MH109977
6 · The paper itself

Abstract

Psychotic disorders are severe, debilitating, and even fatal. The development of targeted and effective interventions for psychosis depends upon on clear understanding of the timing and nature of disease progression to target processes amenable to intervention. Strong evidence suggests early and ongoing neuroprogressive changes, but timing and inflection points remain unclear and likely differ across cognitive, clinical, and brain measures. Additionally, granular evidence across modalities is particularly sparse in the "bridging years" between first episode and established illness-years that may be especially critical for improving outcomes and during which interventions may be maximally effective. Our objective is the systematic, multimodal characterization of neuroprogression through the early course of illness in a cross-diagnostic sample of patients with psychosis. We aim to (1) interrogate neurocognition, structural brain measures, and network connectivity at multiple assessments over the first eight years of illness to map neuroprogressive trajectories, and (2) examine trajectories as predictors of clinical and functional outcomes. We will recruit 192 patients with psychosis and 36 healthy controls. Assessments will occur at baseline and 8- and 16-month follow ups using clinical, cognitive, and imaging measures. We will employ an accelerated longitudinal design (ALD), which permits ascertainment of data across a longer timeframe and at more frequent intervals than would be possible in a single cohort longitudinal study. Results from this study are expected to hasten identification of actionable treatment targets that are closely associated with clinical outcomes, and identify subgroups who share common neuroprogressive trajectories toward the development of individualized treatments.

Indexed as

cognitionfirst episodeimaginglongitudinalpsychosisschizophrenia

Identifiers

PMID32258424
PMCPMC7111514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.